METOLAZONE

Post-LOE

metolazone

Novartis

ANDAORALTABLET2 Generics Approved

Approved

Dec 2003

Lifecycle

Post-LOE

Competitive Pressure

60/100

Clinical Trials

Data completeness

3/8 — Basic

METOLAZONE (metolazone) by Novartis. Approved for thiazide-like diuretic [epc]. First approved in 2003.

Drug data last refreshed 9h ago

Mechanism of Action

Pharmacologic Class:

Thiazide-like Diuretic

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (4)

NCT01617798N/AWithdrawn

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis

Started Jun 2012

Respiratory FailureVolume OverloadHypernatremia

NCT00650195Phase 1Completed

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

Started Feb 2004

56 enrolled

Healthy

NCT00649181Phase 1Completed

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

Started Oct 2003

52 enrolled

Healthy

NCT00649051Phase 1Completed

Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

Started Dec 2002

52 enrolled

Healthy

Company

Worked on METOLAZONE at Novartis? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.